Clinical trials
Stem Cell Transplantation clinical trials
Below are recruiting stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 604 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03214354RecruitingPhase 2
Stem cell transplant for children with sickle cell and ABO mismatch
This trial studies a stem cell transplant approach for children with sickle cell disease, using a sibling donor whose blood type is not compatible. It aims to see if this transplant method can safely reduce serious sickle cell complications.
Calgary, AlbertaAges 1–19 - NCT03279094RecruitingPhase 1
Testing a half-matched bone marrow transplant for sickle cell
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Duarte, CaliforniaAges 1–30 - NCT03378102RecruitingEarly Phase 1
AdV-targeted T cells for adenovirus after bone marrow transplant
This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.
Cleveland, OhioAges 3 months+ - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65 - NCT03562169RecruitingPhase 3
Ixazomib with your own stem cell transplant for relapsed myeloma
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
AberdeenAges 18 years+ - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03719105RecruitingEarly Phase 1
Chemo plus immunotherapy with donor stem cell transplant for NK lymphoma
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Birmingham, AlabamaAges 1–31 - NCT03818334RecruitingPhase 2/Phase 3
Cyclophosphamide after transplant for blood cancer without sibling donor
This trial studies giving cyclophosphamide after a stem cell transplant when there is no matched sibling donor, but a well-matched unrelated donor is available. It aims to improve outcomes for people with blood cancers undergoing this transplant.
São Paulo, São PauloAges 1–75 - NCT03850366RecruitingPhase 2
Haploidentical stem cell transplant with two post-transplant medicines
This trial tests a way to treat certain blood cancers using a stem cell transplant from a partially matched (haploidentical) donor. It aims to make the transplant safer and reduce the chance of the immune reaction that can follow transplant, using post-transplant cyclophosphamide and bortezomib.
Detroit, MichiganAges 18–65 - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04201210RecruitingPhase 2
Stem cell transplant study for young people with severe sickle cell
This Phase 2 study tests a type of stem cell transplant that uses donor immune cells that have been specially “tweaked” to help treat sickle cell disease. It may help prevent serious sickle cell complications, but it requires careful matching and screening of organs and pregnancy status.
ViennaAges 2–35 - NCT04224558RecruitingPhase 1/Phase 2
Stem cell transplant for hard-to-control Crohn’s disease
This early-phase study tests whether a stem cell transplant can improve Crohn’s disease in teens and young adults whose disease is active and not responding to standard medicines. It may help some people who are not doing well despite several prior treatments, but it also involves intensive study procedures and safety checks.
Los Angeles, CaliforniaAges 13–28 - NCT04230356RecruitingPhase 2
Viral immune T-cells for viral infections after stem cell transplant
This Phase 2 study tests donor-made immune T-cells that specifically target viruses to treat or prevent viral infections after a stem cell transplant. It may help your body control dangerous viruses like adenovirus, CMV, EBV, and BK virus, while checking safety with different timing of the treatment.
Cincinnati, OhioAges Any age - NCT04249830Recruiting
Donor stem cell transplant after donor cell targeting in youth
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
Palo Alto, CaliforniaAges 1 month–60 years - NCT04337515Recruiting
Study of a new method to prepare stem cell transplants
This feasibility study tests a technique called CLINIMACS to reduce certain immune cells (alpha/beta T-cells) before a stem cell transplant. It may help make the transplant safer and better controlled, but this is an early-stage feasibility test.
San Francisco, CaliforniaAges Up to 30 years - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT04380831RecruitingEarly Phase 1
Whole-body radiation plus chemo before stem cell transplant
This early-stage trial studies whether giving whole-body radiation and a chemotherapy medicine before an autologous stem cell transplant can improve severe systemic sclerosis. It aims to reset the immune system, but it requires careful safety checks and close follow-up.
Duarte, CaliforniaAges 18–65 - NCT04452305Recruiting
Frozen testicle tissue transplant to restore fertility
This study tests using previously frozen (cryopreserved) testicle cells or tissue to regrow testicular tissue. If you’ve had cancer treatment that can harm fertility, this may help restore natural fertility potential using your own tissue.
Pittsburgh, PennsylvaniaAges Any age - NCT04593589RecruitingPhase 1
Stem cell transplant to protect salivary function after oral cancer
This Phase 1 study tests whether transplanting stem cells into the submandibular gland can help restore saliva function after surgery and radiation for oral cavity squamous cell cancer. You may be considered because you recently had tumor removal and radiation aimed at the neck area, which can damage salivary glands.
GroningenAges 18 years+ - NCT04640987RecruitingPhase 1
Stem cell transplant with added T-cells for blood cancers
This Phase 1 study tests a stem cell transplant plan that uses donor T-cells that have been specially processed and then added back. It aims to see if this approach is safer and works better for children and adults with serious blood cancers who need a transplant.
Palo Alto, CaliforniaAges 1 month–45 years
Hear when a new Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for stem cell transplantation?
- Yes. Clin2 currently lists 604 recruiting stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.